Guarantee the Quality, Safety & Consistency of mRNA, DNA & Viral Vector-Based Vaccines

Over the course of the most recent pandemic, vaccine technologies have developed at an amazing pace. However, none of these platforms would have succeeded without comprehensive analytical support.

As vaccine developers strive to ensure that the entire vaccine development process is as efficient, precise, and cost-effective as possible, the inaugural Genetic Vaccine Analytical Development Summit united large pharma and innovative biotechs to develop the right analytical methods to guarantee the quality, safety, and consistency of mRNA, DNA and viral vector-based vaccines.

The Summit was focused specifically on addressing the unique analytical challenges posed by genetic vaccines, this technical scientific conference will unite analytical scientists, Heads of CMC, Analytical Development, and Pre-Formulation from the leading companies grappling with these challenges first-hand.

Joined by the leading minds in vaccine analytics to optimize the development of better and more robust tools to ensure the safety, quality, and consistency of mRNA, DNA, and viral vector-based vaccines.

2022 Speakers Included:

Jean Boyer

Vice president, Analytical Sciences

INOVIO

Meredith Packer

Scientist, Process & Analytical Development

Moderna

Sean Sullivan

Executive Director

Arcturus Therapeutics

Tom Anchordoquy

Professor, Pharmaceutical Sciences

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado

Darisuh Mohammadyani

Senior Scientist, Computational Drug Disocvery

Janssen

Jessica Townsend

Manager, Analytical Development

bluebird bio

Lawrence Thompson

Senior Principal Scientist, Analytical R&D

Pfizer

Ravi Ganapathy

Head, Vaccine Process Development

International Vaccine Institute

Companies in Attendance Included:

AZ_RGB_H_COL_1200x630
1200px-GSK_logo_2014.svg
Elanco.svg
2560px-Sanofi_logo.svg (1)
Merck_Logo.svg (2)
2seventy_logo_for_BW
Janssen_Pharmaceuticals_logo.svg (1)
malaghan
MEDICAGO_LT_B_RGB
IAVI25_logo-50
moderna
arcturus
Pfizer_new_2021
Nutcracker_Therapeutics_Logo
GreenLightLogo

Testimonials From the Vaccine Community:

“Having the opportunity to hear leading scientists and engineers from academia and industry talk openly about their findings and opinions in the field was an enlightening experience which will take our company far.” – Senior Scientist, Analytical Development – Nutcracker Therapeutics

“The summit was very valuable - with quality speakers and a very relevant content.” – Director, Greenlight Biosciences

“Great insight into analytical strategy development” - Executive Director - Process Development & Manufacturing & Vaccine Development, International AIDS Vaccine Initiative (IAVI)